Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict bladder drug success

NCT ID NCT07773532

Knowledge-focused Sponsor: Bagcilar Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study looks at whether simple blood tests can predict how well women with overactive bladder respond to the drug mirabegron. Researchers will measure inflammation markers in the blood before treatment and see if they relate to symptom improvement after three months. The goal is to help doctors choose the right treatment for each patient, potentially avoiding trial-and-error prescribing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mirabegron 50 mg taken orally once daily, as part of routine care
What this could lead to
If blood inflammation markers predict treatment success, doctors could personalize overactive bladder therapy, saving time and avoiding ineffective treatments.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The markers may not reliably predict response, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 115 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Treatment-naive adult women with overactive bladder attending the urogynecology outpatient clinic of a tertiary referral hospital in Istanbul, Turkey, in whom mirabegron 50 mg is initiated within routine clinical care. Consecutive eligible patients are enrolled.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18 years or older * Overactive bladder symptoms for at least 3 months * Mirabegron 50 mg planned by physician decision within routine care * Ability to provide written informed consent Exclusion Criteria: * Any previous OAB-specific treatment other than behavioral therapy (oral antimuscarinic or beta-3 agonist, intravesical botulinum toxin, sacral neuromodulation, or posterior tibial nerve stimulation) * Acute infection within the last 4 weeks, including culture-confirmed urinary tract infection * Chronic inflammatory disease (rheumatologic or autoimmune disease, or inflammatory bowel disease) * Active malignancy or cancer treatment within the last 5 years * Use of systemic glucocorticoids within the last 4 weeks, or chronic NSAID or immunosuppressive use * Conditions affecting lower urinary tract function other than OAB (neurogenic bladder, urinary tract stones, history of pelvic radiotherapy or bladder surgery, pelvic organ prolapse stage 3 or higher, or stress-predominant mixed urinary incontinence) * Known diagnosis of hematologic disease, anemia (Hb\<9), or platelet disorder (PLT\<100.000 or \>600.000) * Significant renal or hepatic impairment (eGFR below 30 mL/min/1.73 m2, or Child-Pugh class B or C) * Uncontrolled hypertension (180/110 mmHg or higher) or any other contraindication to mirabegron * Pregnancy or lactation * Major surgery or trauma within the last 3 months * Cognitive or functional inability to complete the voiding diary

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overactive bladder (OAB) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation overactive bladder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overactive bladder (OAB)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bagcilar Training and Research Hospital

    Istanbul, Bagcilar, 34200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.